O Shaughnessy Asset Management LLC Decreases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

O Shaughnessy Asset Management LLC reduced its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 38.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 2,363 shares of the biotechnology company’s stock after selling 1,476 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Sarepta Therapeutics were worth $287,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SRPT. Louisiana State Employees Retirement System increased its stake in shares of Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after purchasing an additional 100 shares in the last quarter. Manchester Capital Management LLC grew its holdings in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. UMB Bank n.a. increased its position in Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after buying an additional 138 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 139 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 145 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on SRPT shares. HC Wainwright raised shares of Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 target price for the company in a research note on Wednesday, April 2nd. Wells Fargo & Company started coverage on shares of Sarepta Therapeutics in a research note on Friday. They set an “overweight” rating and a $115.00 price objective on the stock. Scotiabank lowered their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Deutsche Bank Aktiengesellschaft reduced their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $161.83.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $51.03 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market cap of $4.95 billion, a PE ratio of 40.82 and a beta of 0.93. The company’s fifty day simple moving average is $88.11 and its 200-day simple moving average is $110.20. Sarepta Therapeutics, Inc. has a 52 week low of $48.01 and a 52 week high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.